Axsome Therapeutics,Inc. (NASDAQ:AXSM) Files An 8-K Other Events
Item8.01.Other Events.
On February14, 2017, Axsome Therapeutics,Inc. (the Company)
issued a press release announcing that it had received, from the
U.S. Food and Drug Administration, Fast Track designation for one
of the Companys lead product candidates, AXS-05, for the
treatment of treatment resistant depression.
The full text of the press release is filed as Exhibit99.1 hereto
and is incorporated herein by reference.
Item 9.01.Financial Statements and
Exhibits.
(d) Exhibits.
|
Exhibit Number |
|
Description |
|
99.1 |
Press release dated February14, 2017. |
About Axsome Therapeutics, Inc. (NASDAQ:AXSM)
Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders, including pain. It operates in the business of developing novel therapies for the management of CNS disorders segment. Its product candidate, AXS-02 (disodium zoledronate tetrahydrate), is an oral, targeted, non opioid therapeutic for chronic pain. It is developing AXS 02 for the treatment of pain in over three conditions, such as complex regional pain syndrome (CRPS); knee osteoarthritis (OA) associated with bone marrow lesions (BMLs), and chronic low back pain (CLBP), associated with type I, or mixed type I and type II Modic changes (MCs). Its product candidate, AXS 05, is a fixed dose combination of dextromethorphan (DM) and bupropion. It is developing AXS 05 for the treatment of over two conditions, such as treatment resistant depression (TRD), and agitation in patients with Alzheimer’s disease (AD). Axsome Therapeutics, Inc. (NASDAQ:AXSM) Recent Trading Information
Axsome Therapeutics, Inc. (NASDAQ:AXSM) closed its last trading session up +0.15 at 4.75 with 215,197 shares trading hands.
